Hanafusa Norio
The Division of Total Renal Care Medicine, the University of Tokyo Hospital, Japan.
Clin Calcium. 2015 May;25(5):711-21.
Vascular calcification is the abnormality in chronic kidney disease-mineral bone disorder (CKD-MBD) that directly affects the prognosis in relation with cardiovascular diseases. Phosphate binders (PB) are widely used to prevent hyperphosphatemia that can lead to vascular calcification. Two types of PB are available ; calcium (Ca) -based PB and non-Ca-based PB. Non-Ca-based PB has been shown to retard the progression of vascular calcification, while there is a great concern that Ca overload can promote calcification. Moreover, the newer non-Ca-based PBs have been developed including iron and magnesium. We must pay attention to select proper types of PB with costs, pill burdens and specific circumstances observed in Japan.
血管钙化是慢性肾脏病-矿物质和骨异常（CKD-MBD）中的一种异常情况，它直接影响与心血管疾病相关的预后。磷结合剂（PB）被广泛用于预防可导致血管钙化的高磷血症。有两种类型的磷结合剂可供使用；钙（Ca）基磷结合剂和非钙基磷结合剂。已表明非钙基磷结合剂可延缓血管钙化的进展，而人们非常担心钙超载会促进钙化。此外，包括铁和镁在内的新型非钙基磷结合剂也已研发出来。我们必须注意根据成本、服药负担以及在日本观察到的具体情况来选择合适类型的磷结合剂。
